Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

13 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
DAA therapy and long-term hepatic function in advanced/decompensated cirrhosis: Real-world experience from HCV-TARGET cohort.
Verna EC, Morelli G, Terrault NA, Lok AS, Lim JK, Di Bisceglie AM, Zeuzem S, Landis CS, Kwo P, Hassan M, Manns MP, Vainorius M, Akushevich L, Nelson DR, Fried MW, Reddy KR. Verna EC, et al. Among authors: vainorius m. J Hepatol. 2020 Sep;73(3):540-548. doi: 10.1016/j.jhep.2020.03.031. Epub 2020 Mar 31. J Hepatol. 2020. PMID: 32243960 Free article. Clinical Trial.
All-oral direct-acting antiviral therapy in HCV-advanced liver disease is effective in real-world practice: observations through HCV-TARGET database.
Reddy KR, Lim JK, Kuo A, Di Bisceglie AM, Galati JS, Morelli G, Everson GT, Kwo PY, Brown RS Jr, Sulkowski MS, Akuschevich L, Lok AS, Pockros PJ, Vainorius M, Terrault NA, Nelson DR, Fried MW, Manns MP; HCV-TARGET Study Group. Reddy KR, et al. Among authors: vainorius m. Aliment Pharmacol Ther. 2017 Jan;45(1):115-126. doi: 10.1111/apt.13823. Epub 2016 Oct 28. Aliment Pharmacol Ther. 2017. PMID: 27790729
Safety profile of boceprevir and telaprevir in chronic hepatitis C: real world experience from HCV-TARGET.
Gordon SC, Muir AJ, Lim JK, Pearlman B, Argo CK, Ramani A, Maliakkal B, Alam I, Stewart TG, Vainorius M, Peter J, Nelson DR, Fried MW, Reddy KR; HCV-TARGET study group. Gordon SC, et al. Among authors: vainorius m. J Hepatol. 2015 Feb;62(2):286-93. doi: 10.1016/j.jhep.2014.08.052. Epub 2014 Sep 10. J Hepatol. 2015. PMID: 25218788 Free PMC article. Clinical Trial.
Effectiveness and Safety of Sofosbuvir-Based Regimens for Chronic HCV Genotype 3 Infection: Results of the HCV-TARGET Study.
Feld JJ, Maan R, Zeuzem S, Kuo A, Nelson DR, Di Bisceglie AM, Manns MP, Sherman K, Frazier LM, Sterling R, Mailliard M, Schmidt M, Akushevich L, Vainorius M, Fried MW. Feld JJ, et al. Among authors: vainorius m. Clin Infect Dis. 2016 Sep 15;63(6):776-783. doi: 10.1093/cid/ciw387. Epub 2016 Jun 19. Clin Infect Dis. 2016. PMID: 27325691 Free PMC article.
Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET study.
Welzel TM, Nelson DR, Morelli G, Di Bisceglie A, Reddy RK, Kuo A, Lim JK, Darling J, Pockros P, Galati JS, Frazier LM, Alqahtani S, Sulkowski MS, Vainorius M, Akushevich L, Fried MW, Zeuzem S; HCV-TARGET Study Group. Welzel TM, et al. Among authors: vainorius m. Gut. 2017 Oct;66(10):1844-1852. doi: 10.1136/gutjnl-2016-311609. Epub 2016 Jul 13. Gut. 2017. PMID: 27418632 Free PMC article.
Effectiveness of Ledipasvir-Sofosbuvir Combination in Patients With Hepatitis C Virus Infection and Factors Associated With Sustained Virologic Response.
Terrault NA, Zeuzem S, Di Bisceglie AM, Lim JK, Pockros PJ, Frazier LM, Kuo A, Lok AS, Shiffman ML, Ben Ari Z, Akushevich L, Vainorius M, Sulkowski MS, Fried MW, Nelson DR; HCV-TARGET Study Group. Terrault NA, et al. Among authors: vainorius m. Gastroenterology. 2016 Dec;151(6):1131-1140.e5. doi: 10.1053/j.gastro.2016.08.004. Epub 2016 Aug 24. Gastroenterology. 2016. PMID: 27565882 Free PMC article.
Safety and efficacy of current direct-acting antiviral regimens in kidney and liver transplant recipients with hepatitis C: Results from the HCV-TARGET study.
Saxena V, Khungar V, Verna EC, Levitsky J, Brown RS Jr, Hassan MA, Sulkowski MS, O'Leary JG, Koraishy F, Galati JS, Kuo AA, Vainorius M, Akushevich L, Nelson DR, Fried MW, Terrault N, Reddy KR. Saxena V, et al. Among authors: vainorius m. Hepatology. 2017 Oct;66(4):1090-1101. doi: 10.1002/hep.29258. Epub 2017 Sep 4. Hepatology. 2017. PMID: 28504842 Free PMC article.
Safety and Effectiveness of Ledipasvir and Sofosbuvir, With or Without Ribavirin, in Treatment-Experienced Patients With Genotype 1 Hepatitis C Virus Infection and Cirrhosis.
Lim JK, Liapakis AM, Shiffman ML, Lok AS, Zeuzem S, Terrault NA, Park JS, Landis CS, Hassan M, Gallant J, Kuo A, Pockros PJ, Vainorius M, Akushevich L, Michael L, Fried MW, Nelson DR, Ben-Ari Z; HCV-TARGET Study Group. Lim JK, et al. Among authors: vainorius m. Clin Gastroenterol Hepatol. 2018 Nov;16(11):1811-1819.e4. doi: 10.1016/j.cgh.2017.12.037. Epub 2018 Jan 3. Clin Gastroenterol Hepatol. 2018. PMID: 29306043 Free PMC article.
Treatment Status of Hepatocellular Carcinoma Does Not Influence Rates of Sustained Virologic Response: An HCV-TARGET Analysis.
Radhakrishnan K, Di Bisceglie AM, Reddy KR, Lim JK, Levitsky J, Hassan MA, Darling JM, Feld JJ, Akushevich L, Vainorius M, Nelson DR, Fried MW, Brown RS Jr, Terrault NA. Radhakrishnan K, et al. Among authors: vainorius m. Hepatol Commun. 2019 Aug 7;3(10):1388-1399. doi: 10.1002/hep4.1412. eCollection 2019 Oct. Hepatol Commun. 2019. PMID: 31592494 Free PMC article.
13 results